PharmaNova, Inc. (USA) and its European affiliate, PharmaNova Europa, Ltd. are committed to the development of innovative pharmaceutical products which address areas of significant unmet medical need and large pharmaceutical market opportunities. Our lead project is the licensing and development of a prescription non-hormonal  treatment  for menopausal hot flushes/flashes i.e. modified-release gabapentin. We focus on clinical re-positioning and/or re-formulation of known drugs to enhance their properties e.g. absorption, bioavailability, efficacy, safety, or to enable additional routes of administration.    

PharmaNova's proprietary platform technology, NovaSperse℠, primarily targets compounds/APIs that are significantly constrained by poor water solubility.  The creation of nano-particulate formulations of such compounds can elicit profound improvements in their pharmaceutical and biological properties, and consequently offer new options for controlled, targeted drug delivery and clinical use.  Our business model is to create and add value to such opportunities through application of this technology, generate Intellectual Property protecting the new product(s), and progress through development to a stage that provides a commercially attractive opportunity for out-licensing/partnering.  PharmaNova is developing a library of nanoparticle formulations for use in oncology, ophthalmology, and as topical anti-infective agents.

PharmaNova's partnering model is three-fold: 

i)  To out-license PharmaNova's Intellectual Property rights for new product opportunities (NPOs) at a suitable stage of their pharmaceutical or clinical development.  Licensee partners would complete product development, registration, and commercialization.

ii)   To form strategic alliances for the co-development of mutually agreed NPOs.

iii) To conduct work on a client¬-sponsored contractual fee-for-service basis applying our NovaSperse℠ technology to enhance the properties of client-owned APIs.  Technology transfer and Licensing of NovaSperse℠ technology for use with client API would follow a successful pharmaceutical development program.